Cell line · CVCL_2092
Papers57
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 57
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dysregulation of neuronal androgen receptor signaling by divergent collaborative transcription factors in Alzheimer's disease. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor. | Pediatr Blood Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells. | Cancer Genomics Proteomics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity. | Cell Rep | 2024 | Cellosaurus cites it | PubMed | |
| Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer's disease. | Mol Neurodegener | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2092/papers